Does SCNX pay a dividend and is it safe?

Scienture Holdings Inc. (SCNX) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / SCNX / dividends

PCSA (39) ADXN (48) LGVN (27) GELS (54) ⌘ Pro Terminal →

Scienture Holdings Inc. (SCNX) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is SCNX trading relative to its 50-day, 200-day, and 52-week technical levels?

SCNX last traded at $3.22 (-7.74% on volume of 11,393 shares), positioning the stock -46.51% below its 50-day simple moving average ($6.02) and -64.58% below its 200-day simple moving average ($9.09). Across its 52-week range of $2.64 to $27.75, SCNX sits at the 2.3% percentile with a 14-day RSI of 34.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.82 to $3.62).

$3.22 -7.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.17

Scienture Holdings Inc. (SCNX) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $5.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SCNX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SCNX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Scienture Holdings Inc. (NASDAQ: SCNX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $3.22 (-7.74% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SCNX ranks #874 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SCNX compare to PCSA and ADXN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SCNX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 76.8%, and ROIC of -35.0%. By comparison, PCSA (Processa Pharmaceuticals Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M) and ADXN (Addex Therapeutics Ltd) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $5.3M). Among the 5-stock peer group, SCNX leads on earnings multiple (N/A) while SCNX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SCNX?

▼

Per SCNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001382574), Scienture Holdings Inc. generated $431.6K in revenue (+215.9% YoY), -$41.5M in net income, and -$13.4M in free cash flow against $84.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.17 (-1.58%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-13.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SCNX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (28/100 Composite)

🔍 WHY SCNX SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (25% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.24-5.9% Next Q

Q2 (-2Q)

Grade E$3.05+5.9% Next Q

Q3 (-1Q)

Grade E$3.23-0.3% Next Q

Current

Grade E$3.22-10% Hist 90D α

Trajectory: E (36) → E (28)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SCNX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SCNX currently carries a cautious 28/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.02) and Max Pain ($3.38) forces dealer call-delta covering toward $29.14.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SCNX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SCNX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 28%NO 72%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (16.3% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $45,269

Est. Year-10 Shareholder Yield: $815/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.6K

Yr 1

$13.5K

Yr 2

$15.7K

Yr 3

$18.3K

Yr 4

$21.3K

Yr 5

$24.7K

Yr 6

$28.8K

Yr 7

$33.5K

Yr 8

$38.9K

Yr 9

$45.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SCNX)

✓Walkthrough of SCNX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SCNX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -67.04%📐 HORIZONTAL RANGE

2026-11-03O $3.49H $3.49L $3.22C $3.22VOL 11.4K

RES: $12.22SUP: $2.27SMA50: $6.02SMA200: $9.09

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SCNX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SCNX Butterfly Map → + Track SCNX →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +215.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SCNX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SCNX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SCNX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SCNX)

Health Care Rank #874 of 1015 ⚔️ PCSA vs SCNX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SCNX vs. PCSA, ADXN, LGVN, GELS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Scienture Holdings Inc. (SCNX) ranks #874 by composite RQD confidence (28/100, grade E) and #934 by equity capitalization ($5.3M). Within this direct 5-issuer industry benchmark cohort, SCNX leads on earnings valuation at N/A trailing P/E, while SCNX leads on capital efficiency and profitability with -35.0% ROIC and 76.8% gross margin. GELS currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with SCNX at 28/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SCNX ACTIVE Scienture Holdings Inc.	E	28/100	—	76.8%	-35.0%	-7.74%	$5.3M	Benchmark Subject
PCSA Processa Pharmaceuticals Inc.	D-	39/100	—	—	-35.0%	0.00%	$5.3M	/pcsa-vs-scnx →
ADXN Addex Therapeutics Ltd	D	48/100	—	—	—	+5.46%	$5.3M	/adxn-vs-scnx →
LGVN Longeveron Inc. (Class A)	E	27/100	—	67.0%	-35.0%	-4.57%	$5.3M	/lgvn-vs-scnx →
GELS Gelteq Limited	D+	54/100	—	—	—	-3.14%	$5.2M	/gels-vs-scnx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001382574 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scienture Holdings Inc. (SCNX) reported GAAP revenue of $431.6K (+215.9% vs. FY2024 revenue of $136.6K , and -68.4% cumulative change since FY2023) , GAAP net income of -$41.5M, operating cash flow of -$13.4M, and free cash flow of -$13.4M (+6.3% YoY). On the balance sheet, SCNX closed FY2025 with $84.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$431.6K	-$41.5M	-$13.4M	-$13.4M	$84.2M	—
FY2024 (FY)	2024-12-31	$136.6K	$13.6M	-$14.3M	-$14.3M	$104.9M	—
FY2023 (FY)	2023-12-31	$1.4M	-$17.8M	-$2.2M	-$2.2M	—	—

3. SCNX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SCNX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SCNX compare to PCSA and ADXN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SCNX?

Where is SCNX trading relative to its 50-day, 200-day, and 52-week technical levels?

SCNX last traded at $3.22 (-7.74% on volume of 11,393 shares), positioning the stock -46.51% below its 50-day simple moving average ($6.02) and -64.58% below its 200-day simple moving average ($9.09). Across its 52-week range of $2.64 to $27.75, SCNX sits at the 2.3% percentile with a 14-day RSI of 34.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.82 to $3.62).

Direct Sub-Reports: SCNX RQD Cockpit SCNX 12M Forecast SCNX Earnings & Move SCNX Dividends & DRIP SCNX Insiders & 13F SCNX Whale Options SCNX Profit Sankey SCNX News & Why

ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ SEC XBRL & RQD VERIFIED

SCNX — Scienture Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Scienture Holdings Inc. (SCNX) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.22 (-7.74% 1D, market capitalization $5.3M).

Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 76.8%, operating margin of -60.0%, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Scienture Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). Reported gross margin is 76.8%, indicating that the company's cost of revenue is low relative to sales, though revenue is very small in absolute terms (per the market data and SEC financials). — beyond these sector and margin facts.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Scienture Holdings Inc. (SCNX) reported $431.6K in annual revenue (up from $136.6K in FY2024, +215.9% YoY) and -$41.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.4M revenue, -$17.8M net income) through FY2025, SCNX scaled operating cash flow to -$13.4M and free cash flow to -$13.4M, backed by $84.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.64 – $27.75 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies cannot be mapped from source data. A prospective investor should note that the absence of mapped links means no second-order ripples can be identified from the provided material.

Key Question #1: Can SCNX sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $431.6K and free cash flow of -$13.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is SCNX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SCNX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Scienture Holdings Inc. (SCNX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SCNX Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 23h ago

EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability

Yahoo Finance report covering Scienture Holdings Inc. (SCNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Scienture Holdings, Inc. Estimates – NASDAQ:SCNX

TradingView report covering Scienture Holdings Inc. (SCNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST The Globe and Mail • 1d ago

Scienture Holdings Regains Nasdaq Compliance Amid Revenue Surge

The Globe and Mail report covering Scienture Holdings Inc. (SCNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 1d ago

Most Active US Stocks: Heavy Volume Highlights Low-Priced Names

ChartMill report covering Scienture Holdings Inc. (SCNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH kalkine.ca • 1d ago

Scienture Holdings (NASDAQ:SCNX) Penny Stock Falls in a Month on a Split and a Revenue Miss

kalkine.ca report covering Scienture Holdings Inc. (SCNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Thursday's After-Market Session

Benzinga report covering Scienture Holdings Inc. (SCNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

SCNX Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 3.97% - Return On Capital

https://www.dars.gov.et/ report covering Scienture Holdings Inc. (SCNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE SeekingAlpha • 6d ago

Scienture Holdings, Inc. (SCNX) Shareholder/Analyst Call Prepared Remarks Transcript

Scienture Holdings, Inc. (SCNX) Shareholder/Analyst Call October 28, 2026 11:00 AM EDTCompany ParticipantsShankar Hariharan - Founder, Co-CEO &...

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SCNX Bull vs. Bear Conversation Board — What's Your Call at $3.22?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SCNX 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $3.74 (+16.1%)

📌 Pinned Debate

Headlines report revenue soaring 256% and a Nasdaq compliance regain, with management targeting 2027 profitability.

Picked up a starter position in SCNX in my $100K Virtual Cash book at $3.22. Headlines report revenue soaring 256% and a Nasdaq compliance regain, with management targeting 2027 profitability.. Trading inside a $2.64–$27.75 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

VolSurface_Trader 🐂 BULL

@FadeTheHype Shorting a 3/20 institutional whale-flow stock at $3.22 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $2.54 (-21.1%)

Spot @ $3.22

Operating margin of -60% and ROIC of -35% alongside an Altman Z-Score of 0.2 signal severe cash burn and forensic balance sheet risk.

Operating margin of -60% and ROIC of -35% alongside an Altman Z-Score of 0.2 signal severe cash burn and forensic balance sheet risk.. Look at the math on SCNX: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $2.83 before getting long.